

Codexis signs enzyme supply agreement with Kyorin Pharma

11 February 2019 | News

Codexis is a leading protein engineering company that applies its proprietary CodeEvolver technology to develop proteins for a variety of applications.



Codexis, Inc. has recently announced a multi-year, exclusive supply agreement with KYORIN Pharmaceutical Co., Ltd. for the supply of a proprietary enzyme to be used in the manufacture of vibegron, an active ingredient in Beova Tablets, a novel, once-daily treatment for overactive bladder. The product was commercially launched in Japan in November 2018.

Codexis is a leading protein engineering company that applies its proprietary CodeEvolver technology to develop proteins for a variety of applications, including as biocatalysts for the commercial manufacture of pharmaceuticals, fine chemicals and industrial enzymes, and enzymes as biotherapeutics and for use in molecular diagnostics.

“Our CodeEvolver technology enabled a computational design strategy to create an enzyme that eliminates several manufacturing steps and performs in a high-pH environment. This proprietary enzyme will now be used to streamline vibegron manufacturing,” said Codexis President and CEO John Nicols. “This agreement with KYORIN is another example of the significant value our technology brings in developing high-performing, value-added enzymes with utility from R&D to commercial-scale manufacturing. We are delighted to enter into this supply agreement with KYORIN.”